Review
Medicine, Research & Experimental
Zhencong Ye, Yongmei Huang, Jianhao Ke, Xiao Zhu, Shuilong Leng, Hui Luo
Summary: Non-small cell lung cancer (NSCLC) is the most common and deadly malignancy of lung cancer; chemotherapy is gradually withdrawn from the stage of history due to its obvious side effects; researchers are now focusing on targeted drugs for the treatment.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Biochemistry & Molecular Biology
Takshveer Singh, Mortaza Fatehi Hassanabad, Ali Fatehi Hassanabad
Summary: Non-small cell lung cancer (NSCLC) is the most common and fatal type of primary lung malignancies, with poor outcomes despite advances in surgery, chemotherapy, and targeted therapies. Immunotherapy presents opportunities for potential improvements in NSCLC management, with various immunotherapeutics approved for clinical use. Ongoing studies are exploring novel targets, therapeutic vaccination, tumor genome modification, and improvements in drug delivery systems for future advancements in NSCLC treatment.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2021)
Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Lindokuhle M. Ngema, Samson A. Adeyemi, Thashree Marimuthu, Yahya E. Choonara
Summary: There is a growing demand for effective treatment options for non-small-cell lung carcinoma, with the focus on minimizing side effects and increasing efficacy. The development of targeted drug delivery systems and nanoparticle-based therapies could lead to more precise and effective treatments for NSCLC.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Review
Oncology
Tania Losanno, Cesare Gridelli
Summary: Treatment of elderly patients with NSCLC is challenging due to higher risk of comorbidities and deteriorations in physical, organ, and cognitive functions. Targeted therapy and immunotherapy are becoming important options for first-line treatment in elderly patients due to their manageability and fewer side effects compared to cytotoxic chemotherapy. Further investigations are needed to determine the best treatment option for each elderly patient.
CURRENT ONCOLOGY REPORTS
(2021)
Review
Chemistry, Multidisciplinary
Piao Jiang, Bin Liang, Zhen Zhang, Bing Fan, Lin Zeng, Zhiyong Zhou, Zhifang Mao, Quan Xu, Weirong Yao, Qinglin Shen
Summary: Lung cancer is the most rapidly growing malignant tumor with the highest incidence and mortality rates, posing the greatest threat to human health and life. It is currently the leading malignant tumor in males and the second leading malignant tumor in females. In the era of precision medicine, there have been unprecedented changes in the concept and strategy of cancer diagnosis and treatment. Nanotechnology has brought new possibilities for tumor diagnosis and treatment, with nanomaterials playing an important role in tumor imaging, diagnosis, drug delivery, and controlled drug release. This article reviews the advancements in lipid-based nanosystems, polymer-based nanosystems, and inorganic nanosystems in the diagnosis and treatment of non-small-cell lung cancer (NSCLC).
Review
Oncology
Stephanie P. L. Saw, Boon-Hean Ong, Kevin L. M. Chua, Angela Takano, Daniel S. W. Tan
Summary: Despite the advancements in treatment for advanced non-small-cell lung cancer (NSCLC), there is a renewed interest in neoadjuvant strategies for early-stage NSCLC. These strategies, including targeted therapy and immunotherapy, have the potential to greatly impact survival outcomes for early-stage NSCLC patients.
Article
Medicine, General & Internal
John V. Heymach, David Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T. Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck, AEGEAN Invest
Summary: In resectable non-small-cell lung cancer patients, perioperative durvalumab plus neoadjuvant chemotherapy showed significantly improved event-free survival and pathological complete response compared to neoadjuvant chemotherapy alone, with a similar safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Domenico Galetta, Lorenzo Spaggiari
Summary: This study reviewed patients who underwent completion pneumonectomy for recurrent/second NSCLC and evaluated the effect of induction therapy (IT) on postoperative outcomes. The results showed that postoperative complications were not influenced by IT, but long-term survival was affected by several factors including the absence of IT, presence of squamous cell carcinoma, and advanced stages of the tumor.
Article
Medicine, General & Internal
Sang Ah Chi, Hyeyeon Yu, Yoon-La Choi, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Dae-Ho Choi, Kyunga Kim, Hyun Ae Jung, Keunchil Park
Summary: This study investigated outcomes associated with new treatment of non-small cell lung cancer (NSCLC) in a clinical setting. The study found that over the past 10 years, there have been continuous advancements in the treatment of NSCLC, leading to improved survival outcomes for patients. Importantly, the study also observed an increase in the proportion of never smokers among lung cancer patients and an increased use of molecular testing.
Article
Engineering, Environmental
Lingxia Liang, Liewei Wen, Yuqing Weng, Jiaxing Song, Honghui Li, Ying Zhang, Xu He, Wei Zhao, Meixiao Zhan, Yong Li, Ligong Lu, Yongjie Xin, Cuixia Lu
Summary: This study developed a novel nanocomplex that can deliver therapeutic cargos to tumors and enhance the chemotherapeutic efficacy by generating hydroxyl radicals through cascade reactions, as well as converting immunologically cold tumors to hot tumors by triggering immunogenic tumor cell death. The nanocomplexes show promise as a treatment strategy for NSCLC through combining targeted therapy and immunotherapy.
CHEMICAL ENGINEERING JOURNAL
(2021)
Article
Medicine, General & Internal
Mariano Provencio, Ernest Nadal, Jose L. Gonzalez-Larriba, Alex Martinez-Marti, Reyes Bernabe, Joaquim Bosch-Barrera, Joaquin Casal-Rubio, Virginia Calvo, Amelia Insa, Santiago Ponce, Noemi Reguart, Javier de Castro, Joaquin Mosquera, Manuel Cobo, Andres Aguilar, Guillermo Lopez Vivanco, Carlos Camps, Rafael Lopez-Castro, Teresa Moran, Isidoro Barneto, Delvys Rodriguez-Abreu, Roberto Serna-Blasco, Raquel Benitez, Carlos Aguado de la Rosa, Ramon Palmero, Florentino Hernando-Trancho, Javier Martin-Lopez, Alberto Cruz-Bermudez, Bartomeu Massuti, Atocha Romero
Summary: This study evaluated the efficacy of the neoadjuvant nivolumab plus chemotherapy regimen on operable stage III non-small-cell lung cancer (NSCLC) patients. The results showed that patients receiving the combination therapy had a higher rate of pathological complete response and longer survival, indicating the effectiveness of this treatment approach in this patient population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Kathryn C. Arbour, Hira Rizvi, Andrew J. Plodkowski, Matthew D. Hellmann, Andrea Knezevic, Glenn Heller, Helena A. Yu, Marc Ladanyi, Mark G. Kris, Maria E. Arcila, Charles M. Rudin, Piro Lito, Gregory J. Riely
Summary: The study found that NSCLC patients with KRAS G12C mutations have similar clinical characteristics and treatment responses to those with KRAS non-G12C mutations, with no significant differences in response to immune checkpoint inhibitors.
CLINICAL CANCER RESEARCH
(2021)
Article
Immunology
Zhengyu Yang, Ya Chen, Yanan Wang, Minjuan Hu, Fangfei Qian, Yanwei Zhang, Bo Zhang, Wei Zhang, Baohui Han
Summary: This retrospective study compared the efficacy and safety of pembrolizumab plus chemotherapy and chemotherapy monotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). The results showed that pembrolizumab plus chemotherapy achieved longer progression-free survival (PFS) and overall survival (OS) in the overall population. Subgroup analysis indicated that patients with positive PD-L1 expression, stage IV, good performance score (ECOG-PS <2), fewer comorbidities (simplified comorbidity score <9) or female patients benefited more significantly from pembrolizumab plus chemotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Laura Bonanno, Ilaria Attili, Alberto Pavan, Matteo Sepulcri, Giulia Pasello, Federico Rea, Valentina Guarneri, PierFranco Conte
Summary: Treatment options for elderly LA-NSCLC patients are limited by age and health conditions, with a lack of clinical trial data and controversies surrounding the use of multimodal treatment.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Oncology
Vijaya R. Bhatt, Christopher Wichman, Thuy T. Koll, Alfred L. Fisher, Tanya M. Wildes, Ann Berger, James O. Armitage, Sarah A. Holstein, Lori J. Maness, Krishna Gundabolu
Summary: A study on older adults with AML receiving chemotherapy showed significant comorbidity burden and functional impairments at baseline, but cognitive and physical function improvements or stability, as well as improved depression scores, were observed in a high proportion of patients at three months post-treatment, indicating success of treatment.
JOURNAL OF GERIATRIC ONCOLOGY
(2024)
Correction
Oncology
Darren J. Walsh, Laura J. Sahm, Michelle O'Driscoll, Bronagh Bolger, Hitam Ameen, Michelle Hannan, Caitriona Goggin, Anne M. Horgan
JOURNAL OF GERIATRIC ONCOLOGY
(2024)
Article
Oncology
Eva Futtrup Maksten, Lasse Hjort Jakobsen, Boris Modrau, Hilde Jensvoll, Kristian Hay Kragholm, Judit Meszaros Jorgensen, Michael Roost Clausen, Robert Schou Pedersen, Andriette Dessau-Arp, Thomas Stauffer Larsen, Christian Bjorn Poulsen, Anne Ortved Gang, Peter Brown, Tarec C. El-Galaly, Marianne Tang Severinsen
Summary: The risk of developing dementia is not increased after lymphoma treatment among patients.
JOURNAL OF GERIATRIC ONCOLOGY
(2024)
Review
Oncology
P. A. L. Nelleke Seghers, Marije E. Hamaker, Shane O'Hanlon, Johanneke E. A. Portielje, Hans Wildiers, Pierre Soubeyran, Annemarie Coolbrandt, Siri Rostoft
Summary: This study identified a core set of symptoms to monitor in older patients with multimorbidity treated for cancer. These symptoms include those related to cancer, treatment side effects, functional decline, and destabilization of comorbidities. The results provide a basis for guiding symptom monitoring during cancer treatment.
JOURNAL OF GERIATRIC ONCOLOGY
(2024)